Tags : $165M

Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for

Shots: Sarepta exercises its option to acquire Myonexus Therapeutics, in all stock transaction for $165M with its five Limb-girdle muscular dystrophy (LGMDs) gene therapies programs i.e LGMD2E, LGMD2D, LGMD2B, LGMD2L & LGMD2C In May,2018 Sarepta and Myonexus collaborated to develop and advance multiple gene therapy programs for LGMD, paying $60M upfront & milestones, gaining excsluive […]Read More